<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00235287</url>
  </required_header>
  <id_info>
    <org_study_id>RAS-block study</org_study_id>
    <nct_id>NCT00235287</nct_id>
  </id_info>
  <brief_title>Pulse Wave Velocity, Pulse Wave Morphology and Blocking of the Reninangiotensin System in Patients With Chronic Kidney Disease</brief_title>
  <official_title>Pulse Wave Velocity, Pulse Wave Morphology and Blocking of the Reninangiotensin System in Patients With Chronic Kidney Disease: An Interventional and Methodological Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Herlev Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Herlev Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether a combination therapy with
      angiotensin-converting enzyme (ACE)-inhibitors and angiotensin receptor blockers reduces the
      arterial stiffness assessed by applantiontonometry more than a single treatment in kidney
      patients.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2005</start_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>pulse wave velocity (aortic and brachial)</measure>
    <time_frame>0, 8, 16 and 24 weeks after start of intervention</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>augmentation index</measure>
    <time_frame>0, 8, 16 and 24 weeks after start of intervention</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>blood pressure (brachial and aortic)</measure>
    <time_frame>0, 8, 16 and 24 weeks after start of intervention</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>buckbergs index</measure>
    <time_frame>0, 8, 16 and 24 weeks after start of interven</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time to reflection</measure>
    <time_frame>0, 8, 16 and 24 weeks after start of interven</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pulse pressure</measure>
    <time_frame>0, 8, 16 and 24 weeks after start of interven</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in glomerular filtration rate (GFR)</measure>
    <time_frame>0, 8, 16 and 24 weeks after start of interven</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>blood parameters</measure>
    <time_frame>at start of intervention and after each 2.5 - 3.week in the study period</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Kidney Failure, Chronic</condition>
  <condition>Cardiovascular Diseases</condition>
  <arm_group>
    <arm_group_label>A,AIIA</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>24 weeks of treatment with Candesartan, where Enalapril is added in the last 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>A, ACE-I</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>24 weeks of treatment with Enalapril, where Candesartan is added in the last 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C, AIIA</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>8 weeks of treatment with Candesartan, followed by 8 weeks of treatment with Enalapril. The treatment in the last 8 out of the 24 weeks is a combination of Candesartan and Enalapril.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C, ACE</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>8 weeks of treatment with Enalapril in incremental doses (5,10,20 mg) , followed by 8 weeks of treatment with Candesartan in incremental doses (4,8,16 mg) . The treatment in the last 8 out of the 24 weeks is a combination of Candesartan 16 mg and Enalapril in incremental doses (5,10,20 mg)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Candesartan and enalapril</intervention_name>
    <description>24 weeks of treatment with Candesartan in incremental doses (4,8,16 mg), where Enalapril is added in incremental doses (5,10 and 20 mg)the last 8 weeks.</description>
    <arm_group_label>A,AIIA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>candesartan and enalapril</intervention_name>
    <description>24 weeks of treatment with Enalapril in incremental doses (5, 10, 20 mg), where Candesartan is added in incremental doses (4,8,16 mg) in the last 8 weeks.</description>
    <arm_group_label>A, ACE-I</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>candesartan and enalapril</intervention_name>
    <description>8 weeks of treatment with Candesartan in incremental doses (4,8,16 mg), followed by 8 weeks of treatment with Enalapril in incremental doses (/5,10,20 mg). The treatment in the last 8 out of the 24 weeks is a combination of Candesartan in incremental doses (4,8,16 mg) and Enalapril 20 mg.</description>
    <arm_group_label>C, AIIA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>candesartan and enalapril</intervention_name>
    <description>8 weeks of treatment with Enalapril in incremental doses (5,10,20 mg), followed by 8 weeks of treatment with Candesartan (4,8,16 mg). The treatment in the last 8 out of the 24 weeks is a combination of Candesartan 16 mg and Enalapril in incremental doses (5,10,20 mg)</description>
    <arm_group_label>C, ACE</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Creatinine: 150-350 micromol/L

          -  Blood pressure &gt; 110 systolic

          -  Negative pregnancy test for fertile women

          -  Written and oral informed consent from the patient

        Exclusion Criteria:

          -  Treatment with both ACE-inhibitors (ACE-I) and angiotensin receptor blockers

          -  Pregnancy or breastfeeding

          -  Treatment with immunosuppressive medication, steroids or non-steroidal
             anti-inflammatory drugs (NSAIDs)

          -  Serious chronic heart failure (New York Heart Association [NYHA] III-IV)

          -  Chronic liver disease

          -  Suspicion or verified kidney artery stenosis

          -  Cardiac arrhythmia and/or implanted pacemaker

          -  Myocardial infarction or cerebrovascular incidence within the last 3 months

          -  Allergy towards ACE-I or angiotensin receptor blockers

          -  Amputation of a whole extremity or the crural or femoral part of the leg

          -  Dementia or a psychological condition that makes understanding of the examination
             conditions impossible

          -  Dialysis or renal transplantation

          -  Treatment with aldosterone antagonists

          -  Hyperkalemia &gt; 5.5 mmol/l

          -  Another serious chronic non-renal disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marie Frimodt-Møller, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dept. of Nephrology, Herlev University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marie Frimodt-Møller, MD</last_name>
    <phone>+ 45 44 88 44 88</phone>
    <phone_ext>84878</phone_ext>
    <email>marfri01@heh.regionh.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Arne H Nielsen, MD, Prof.</last_name>
    <phone>+ 45 44 88 44 88</phone>
    <phone_ext>82277</phone_ext>
    <email>arhn@heh.regionh.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Dept. of Nephrology, Herlev University Hospital</name>
      <address>
        <city>Herlev</city>
        <zip>2730</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie Frimodt-Møller, MD</last_name>
      <phone>+ 45 44 88 44 88</phone>
      <phone_ext>84878</phone_ext>
      <email>marfri01@heh.regionh.dk</email>
    </contact>
    <contact_backup>
      <last_name>Arne H Nielsen, MD, Prof.</last_name>
      <phone>+ 45 44 88 44 88</phone>
      <phone_ext>82277</phone_ext>
      <email>arhn@heh.regionh.dk</email>
    </contact_backup>
    <investigator>
      <last_name>Marie Frimodt-Møller, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>January 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 6, 2005</study_first_submitted>
  <study_first_submitted_qc>October 6, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 10, 2005</study_first_posted>
  <last_update_submitted>January 16, 2009</last_update_submitted>
  <last_update_submitted_qc>January 16, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 19, 2009</last_update_posted>
  <responsible_party>
    <name_title>Marie Frimodt-Møller, MD</name_title>
    <organization>Dept. of Nephrology, Herlev Hospital</organization>
  </responsible_party>
  <keyword>Angiotensin-Converting Enzyme Inhibitors</keyword>
  <keyword>type 1 angiotensin receptor antagonists</keyword>
  <keyword>blood pressure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Candesartan</mesh_term>
    <mesh_term>Candesartan cilexetil</mesh_term>
    <mesh_term>Enalapril</mesh_term>
    <mesh_term>Enalaprilat</mesh_term>
    <mesh_term>Angiotensin Receptor Antagonists</mesh_term>
    <mesh_term>Angiotensin-Converting Enzyme Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

